SPRB logo

SPRB
Spruce Biosciences Inc

4,989
Mkt Cap
$86.15M
Volume
30,144.00
52W High
$240.00
52W Low
$4.28
PE Ratio
-1.19
SPRB Fundamentals
Price
$64.41
Prev Close
$62.79
Open
$62.64
50D MA
$72.23
Beta
1.03
Avg. Volume
53,231.86
EPS (Annual)
-$50.83
P/B
2.03
Rev/Employee
$0.00
$18.61
Loading...
Loading...
News
all
press releases
Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results
Spruce Biosciences (NASDAQ:SPRB - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($9.58) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Given New $170.00 Price Target at Citizens Jmp
Citizens Jmp lowered their price target on shares of Spruce Biosciences from $180.00 to $170.00 and set a "market outperform" rating on the stock in a research note on Tuesday...
MarketBeat·1d ago
News Placeholder
Spruce Biosciences (NASDAQ:SPRB) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $200.00 price target on shares of Spruce Biosciences in a research report on Tuesday...
MarketBeat·1d ago
News Placeholder
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·2d ago
News Placeholder
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·2d ago
News Placeholder
Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday
Spruce Biosciences (NASDAQ:SPRB) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
Spruce Biosciences to Present at Upcoming Investor Conferences in March
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire·9d ago
News Placeholder
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Analysts
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have earned a consensus rating of "Hold" from the eight ratings firms that are covering the stock, MarketBeat.com reports. One...
MarketBeat·9d ago
News Placeholder
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference
Executives from Spruce Biosciences (NASDAQ:SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company's lead program in Sanfilippo syndrome type B (MPS...
MarketBeat·10d ago
News Placeholder
HC Wainwright Has Positive Outlook for SPRB FY2025 Earnings
Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings estimates for shares of Spruce Biosciences in a note issued to investors on...
MarketBeat·17d ago
<
1
2
...
>

Latest SPRB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.